Neogene Therapeutics, Inc., with a $110m series A venture capital round, led a group of five biopharmaceutical companies that revealed $320m in significant VC financings on a single day.
The New York- and Amsterdam-based developer of personalized neoantigen T-cell therapies topped the mega-Monday group of venture capital deals, but two other companies announced financings of more than $70m on 14 September – Escient Pharmaceuticals